Clinical Trial Update: A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA [Phase 2]

View source ↗

Summary

Phase 2 trial characterizing PK/PD of intravenous ferric carboxymaltose (IV FCM) in pediatric patients 1-17 with iron deficiency anemia, completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• intravenous ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Iron Deficiency Anemia (IDA) | Phase 2 | Status: COMPLETED | Results posted: 2017-11-29